Aducanumab, the Alzheimer’s disease drug from Biogen and Eisai that was controversially approved in the US in June, is among four products nearing the end of the EU marketing review cycle that the European Medicines Agency has scheduled for an oral explanation meeting this week.
The oral explanation meeting for aducanumab (US brand name Aduhelm) was due to take place on 9 November, according to the agenda of the latest monthly meeting of the EMA’s human medicines committee, the CHMP, which is running between 8-11 November